Table 2.

Cox proportional hazards model analysis of prognostic factors in patients with advanced NSCLCs who were treated with gefitinib

VariablesHazard ratio (95% CI)P
Univariate analysis
    Amphiregulin (+/−)2.235 (1.050-4.761)0.037 *
    TGF-α (+/−)3.315 (1.557-7.059)0.002 *
    Amphiregulin or TGF-α (+/−)2.510 (1.197-5.262)0.016 *
    Age (≧65/<65 y)1.044 (0.487-2.237)0.912
    Gender (male/female)1.555 (0.685-3.532)0.291
    Histologic type (others/ADC)1.613 (0.648-4.013)0.309
    Disease stage (IIIB/others)1.098 (0.445-2.706)0.8390
    PS (2/0-1)6.707 (2.544-17.682)<0.001 *
    Smoking history (smoker/never smoker)1.596 (0.736-3.462)0.237
Multivariate analysis
    Amphiregulin (+/−)1.042 (0.384-2.825)0.935
    TGF-α (+/−)2.457 (1.072-5.625)0.034 *
    PS (2/0-1)4.792 (1.420-16.171)0.012 *
  • * P < 0.05.